﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Medical Journal of Tabriz University of Medical Sciences</JournalTitle>
      <Issn>2783-2031</Issn>
      <Volume>39</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2018</Year>
        <Month>02</Month>
        <DAY>05</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Study of PAI-1 -675 4G/5G Polymorphism among patients with breast cancer from North West of Iran</ArticleTitle>
    <FirstPage>81</FirstPage>
    <LastPage>85</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mahdieh</FirstName>
        <LastName>Younesi</LastName>
      </Author>
      <Author>
        <FirstName>Mohammadali</FirstName>
        <LastName>Hosseinpour Feizi</LastName>
      </Author>
      <Author>
        <FirstName>Nasser</FirstName>
        <LastName>Pouladi</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2017</Year>
        <Month>12</Month>
        <Day>09</Day>
      </PubDate>
    </History>
    <Abstract>Background: Previous studies have shown the association of genetic factors such as PAI-1 4G/5G polymorphism with susceptibility to breast cancer patients. The aim of this study was to investigate the effect of this polymorphism in breast cancer patients from North West of Iran. Methods: 160 breast cancer patients and 160 healthy individuals were selected. Peripheral blood-DNA samples were taken and used for PCR amplification using the allele specific primers. Results: Based on molecular studies, all patients and control group were divided into three genotypes 4G/4G, 4G/5G and 5G/5G. Genotype distribution between patients (11.25%, 71.25% and 17.50%, respectively) and controls (10.62%, 71.87% and 17.50%, respectively). Additionally, the frequencies of the 4G and 5G alleles between patients (46.87% and 53.12%, respectively) and control group (46.56% and 53.43%, respectively). Conclusion: The genotypic and allelic frequencies of PAI-1 4G/5G polymorphism showed no significant difference between breast cancer patients and control individuals in this cohort.</Abstract>
  </Article>
</ArticleSet>